Physician profile
William E Philippi
NPI 1881692010
$13,423.16
in general payments reported to CMS, 2019-2025
60 companies · $2,250 in 2025
The $2,250 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,099 · 2020: $475 · 2021: $1,067 · 2022: $4,089 · 2023: $1,996 · 2024: $2,447 · 2025: $2,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,693.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,846.20 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $853.98 | 2019-2025 | |
| Amgen INC. | $831.42 | 2019-2025 | Uplizna, Aimovig |
| Mdd US Operations, LLC | $604.58 | 2022-2024 | Gocovri, Gocovri |
| Ucb, INC. | $577.22 | 2021-2025 | Briviact, Nayzilam, Rystiggo |
| Emd Serono, INC. | $464.74 | 2022-2025 | Mavenclad |
| Biogen, INC. | $437.61 | 2021-2025 | Vumerity, Leqembi, Tysabri |
| Sk Life Science, INC. | $432.34 | 2022-2025 | |
| Eisai INC. | $409.52 | 2021-2025 | |
| Lundbeck LLC | $380.40 | 2021-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $314.81 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Janssen Pharmaceuticals, INC | $296.93 | 2021-2023 | Ponvory |
| Pfizer INC. | $269.00 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $243.95 | 2022-2025 | Ingrezza, Ongentys |
| Argenx US, INC. | $241.97 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Philippi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.